The specialist in small molecule drug development has summarised its recent activity, ahead of today’s AGM. On the Chk 1 program out-licensed to Sierra Oncology (NASDAQ:SRRA), Sierra has been helping to stack the odds of future clinical success of SRA737 in its favour by prioritising patients with high-grade serous ovarian cancer, where data suggests that genetically prescreened patients could have a strong chance of responding favourably. A clinical trial data update is now expected to
18 Dec 2018
2018 – A year of significant corporate and clinical progress
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
2018 – A year of significant corporate and clinical progress
Sareum Holdings plc (SAR:LON) | 10.8 0 0.0% | Mkt Cap: 7.71m
- Published:
18 Dec 2018 -
Author:
Derren Nathan -
Pages:
6
The specialist in small molecule drug development has summarised its recent activity, ahead of today’s AGM. On the Chk 1 program out-licensed to Sierra Oncology (NASDAQ:SRRA), Sierra has been helping to stack the odds of future clinical success of SRA737 in its favour by prioritising patients with high-grade serous ovarian cancer, where data suggests that genetically prescreened patients could have a strong chance of responding favourably. A clinical trial data update is now expected to